Research Article

You have full text access to this OnlineOpen article

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

  1. M. Weinblatt1,*,
  2. B. Combe2,
  3. A. Covucci3,
  4. R. Aranda3,
  5. J. C. Becker3,
  6. E. Keystone4

Article first published online: 31 AUG 2006

DOI: 10.1002/art.22070

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 9, pages 2807–2816, September 2006

Additional Information

How to Cite

Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J. C. and Keystone, E. (2006), Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis & Rheumatism, 54: 2807–2816. doi: 10.1002/art.22070

Author Information

  1. 1

    Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    Hopital Lapeyronie, Montpellier, France

  3. 3

    Bristol-Myers Squibb, Princeton, New Jersey

  4. 4

    Mount Sinai Hospital, Toronto, Ontario, Canada

*Rheumatology and Immunology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

Publication History

  1. Issue published online: 31 AUG 2006
  2. Article first published online: 31 AUG 2006
  3. Manuscript Accepted: 9 JUN 2006
  4. Manuscript Received: 15 FEB 2006

Funded by

  • Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (174K)

REFERENCES

  • 1
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16.
  • 2
    Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13: 559–75.
  • 3
    Chambers CA, Allison JP. CTLA-4—the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 1999; 64: 303–12.
  • 4
    Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907–15.
  • 5
    Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263–71.
    Direct Link:
  • 6
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114–23.
  • 7
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 8
    Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502.
    Direct Link:
  • 9
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 10
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625–30.
    Direct Link:
  • 11
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 12
    Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865–76.
  • 13
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412–9.
    Direct Link:
View Full Article (HTML) Get PDF (174K)